高级检索
当前位置: 首页 > 详情页

Identification and Exploration of Serine Peptidase Inhibitor Kazal Type I (SPINK1) as a Potential Biomarker Correlated with the Progression of Non-Small Cell Lung Cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Laboratory Medicine, Key Laboratory of Diagnostic Medicine (Ministry of Education), Chongqing Medical University, Chongqing, People’s Republic of China [2]Department of Laboratory Medicine, Qilu Hospital of Shandong University (Qingdao), Qingdao, Shandong, People’s Republic of China [3]School of Computer Science, Chongqing Institute of Engineering, Chongqing, People’s Republic of China [4]Department of Laboratory Medicine, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, People’s Republic of China [5]Department of Laboratory Medicine, The First People’s Hospital of Longquanyi District Chengdu, Sichuan, People’s Republic of China [6]Chongqing Qiujing High School, Chongqing, People’s Republic of China
出处:
ISSN:

关键词: SPINK1 NSCLC Proliferation Signaling pathway

摘要:
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Although significant advances have been achieved in the treatment of NSCLC during the past two decades, the 5-year survival rate of patients with NSCLC remains <20%. Thus, there is an urgent requirement to further understand the molecular mechanisms that promote NSCLC development and to identify novel therapeutic targets. In the present study, the gene expression profiles of patients with NSCLC from The Cancer Genome Atlas database were carefully analyzed and SPINK1 was identified as a tumor-inducing factor. SPINK1 expression level was found to be increased in both NSCLC tissues and cell lines. Moreover, SPINK1 promoted cell proliferation in A549 and H1299 cells. Knockdown of SPINK1 could activate cell autophagy and apoptosis. Mechanistically, SPINK1 was demonstrated to induce the proliferation of NSCLC via activating the MEK/ERK signaling pathway. In conclusion, these findings suggested that SPINK1 may serve as a potential biomarker in NSCLC.© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 生物学
小类 | 4 区 细胞生物学 4 区 生物物理 4 区 生化与分子生物学
最新[2023]版:
大类 | 4 区 生物学
小类 | 4 区 生化与分子生物学 4 区 生物物理 4 区 细胞生物学
第一作者:
第一作者机构: [1]Department of Laboratory Medicine, Key Laboratory of Diagnostic Medicine (Ministry of Education), Chongqing Medical University, Chongqing, People’s Republic of China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43370 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号